Get the Stockscreener App
9.64
6.86%
-0.71
Alumis Inc stock is traded at $9.64, with a volume of 244.99K.
It is down -6.86% in the last 24 hours and down -19.87% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
See More
Previous Close:
$10.35
Open:
$10.36
24h Volume:
244.99K
Relative Volume:
1.61
Market Cap:
$524.49M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-10.82%
1M Performance:
-19.87%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$9.075
$10.36
1-Week Range:
$8.225
$10.98
52-Week Range:
$8.225
$13.50
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ALMS | 9.64 | 524.49M | 0 | 0 | 0 | 0.00 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Alumis Inc Stock (ALMS) Latest News
Alumis Inc. Reports Q3 2024 Financial Results and Advances Clinical Programs - MSN
Protagonist, J&J’s oral IL-23 psoriasis data strong (but short) - BioWorld Online
What is HC Wainwright's Forecast for Alumis FY2024 Earnings? - MarketBeat
Leerink Partnrs Has Weak Estimate for Alumis FY2024 Earnings - MarketBeat
Alumis Presents Data Highlighting ESK-001's Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024 - The Manila Times
Alumis' ESK-001 Shows Promise in Lupus Treatment, New Clinical Data Revealed at ACR 2024 | ALMS Stock News - StockTitan
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve
Towerview LLC Buys 70,000 Shares of Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis (NASDAQ:ALMS) Price Target Lowered to $26.00 at HC Wainwright - MarketBeat
Alumis (NASDAQ:ALMS) Given Overweight Rating at Cantor Fitzgerald - MarketBeat
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements - The Manila Times
Alumis Reports 93% Success in Psoriasis Trial, Q3 Loss Widens to $93.1M | ALMS Stock News - StockTitan
Analysts Set Alumis Inc. (NASDAQ:ALMS) Price Target at $27.50 - MarketBeat
U.S. Energy (NASDAQ:USEG) Earns Sell Rating from Analysts at StockNews.com - Defense World
Chase (NYSE:CCF) Coverage Initiated by Analysts at StockNews.com - Defense World
Eventbrite, Inc. (NYSE:EB) Receives Average Rating of “Hold” from Brokerages - Defense World
Alumis readies $300 million IPO ahead of Phase 3 trial for plaque psoriasis drug - MSN
Uveitis Clinical Trials 2024: FDA Approvals, Medication, - openPR
How to Take Advantage of moves in (ALMS) - Stock Traders Daily
New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD - Quantisnow
Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference - StockTitan
Net Present Value Model: Alumis Inc’s ESK-001 - GlobalData
Alumis (NASDAQ:ALMS) Rating Increased to Strong-Buy at Baird R W - MarketBeat
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Robert W. Baird Begins Coverage on Alumis (NASDAQ:ALMS) - MarketBeat
Baird starts Alumis coverage with Outperform, $25 target - Investing.com India
Baird starts Alumis coverage with Outperform, $25 target By Investing.com - Investing.com South Africa
When (ALMS) Moves Investors should Listen - Stock Traders Daily
Blue Trust Inc. Purchases 307 Shares of Watsco, Inc. (NYSE:WSO) - Defense World
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - MSN
Alumis (NASDAQ:ALMS) Stock Price Down 4.5%Time to Sell? - MarketBeat
Alumis (NASDAQ:ALMS) Trading 3.1% HigherWhat's Next? - MarketBeat
HC Wainwright Predicts Alumis' Q3 Earnings (NASDAQ:ALMS) - MarketBeat
Analysts Set Curbline Properties (NYSE:CURB) PT at $24.19 - Defense World
Ambev (NYSE:ABEV) Now Covered by StockNews.com - Defense World
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside - AOL
Alumis (NASDAQ:ALMS) Shares Gap UpHere's Why - MarketBeat
H.C. Wainwright sets Buy rating on Alumis stock, cites TYK2 inhibitor - Investing.com
H.C. Wainwright sets Buy rating on Alumis stock By Investing.com - Investing.com UK
Alumis Inc. (NASDAQ:ALMS) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
(ALMS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Shifts in the Psoriasis Market Suggest Strong Potential for Emerging Oral Therapies - GlobeNewswire Inc.
Alumis (NASDAQ:ALMS) Stock Price Down 2.6%What's Next? - MarketBeat
Alumis (NASDAQ:ALMS) Shares Up 6.9%What's Next? - MarketBeat
Millennium Management LLC Takes Position in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Squarepoint Ops LLC Has $240,000 Stock Holdings in Forge Global Holdings, Inc. (NYSE:FRGE) - Defense World
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' - Benzinga
Cramer's Lightning Round: 'I like Target right here' - CNBC
Uveitis Market Growth to Accelerate in Forecast Period - openPR
Alumis (NASDAQ:ALMS) Trading Up 3.8%Time to Buy? - MarketBeat
(ALMS) Technical Pivots with Risk Controls - Stock Traders Daily
Alumis Inc Stock (ALMS) Financials Data
There is no financial data for Alumis Inc (ALMS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):